Cardiovascular News

New analysis of the PROTECTED TAVR trial, which investigated the use of Boston Scientific's Sentinel cerebral embolic protection device has shown a difference in the rate of stroke recorded among patients treated inside and outside of the USA. These findings could have implications for future trials investigating similar technologies, investigators have said https://lnkd.in/epznm6CY

ESC 2024: RESHAPE-HF2 results move conversation forward on effectiveness of TEER in functional MR The trial’s principal investigator, Stefan Anker (Charite University Hospital, Berlin, Germany) said the findings should provide reassurance about the benefits of TEER using the MitraClip device (Abbott) in patients with moderate to severe functional MR and heart failure and could strengthen and broaden recommendations for its future use. Critics, however, are less enthusiastic about the conclusions. Watch the full interview here: https://lnkd.in/eHrabrnS

Is it better to intervene early in patients with severe, asymptomatic aortic stenosis? Yes, say investigators of the EARLY TAVR trial, presented at TCT 2024 in Washington, DC. The findings of the trial suggest that instead of waiting for symptoms to progress, physicians may now have the evidence to justify an early intervention in patients with evidence of severe aortic stenosis. Read more here: https://lnkd.in/eZ8vi6ep

An adjustable transcatheter valve replacement system from Symbiosis —Valsync—has been chosen as the recipient of the Shark Tank innovation prize at the 2024 TCT conference. The Valysnc system comprises two highly compliant balloons, made of a flexible deformable material that can expand to fit the surrounding valve anatomy. Read more here: https://lnkd.in/enQfj6fJ

Whether you have made it to Washington DC for TCT 2024 or watching from afar, keep in touch for the major stories from the meeting with our live blog, that will be updated throughout the four-day event. https://lnkd.in/eY4jr-zr

Medtronic has received US FDA IDE approval to initiate its pivotal clinical trial of the Prevail coronary paclitaxel DCB for ISR and de novo small vessel disease The trial will include a randomised evaluation of ISR patients (compared to Boston Scientific's Agent DCB) and a single arm evaluation of de novo small vessel disease patients to assess the safety and efficacy of the Prevail DCB Azeem Latib Bruno Scheller Darren Mylotte David Kandzari https://lnkd.in/g5R-wvpP

Patients awaiting cardiac surgery who underwent a digital “prehabilitation” programme benefited from an improvement in MACE compared to patients who did not undergo the same intervention prior to their surgery, results of the Digital Cardiac Counseling Trial presented at EACTS 2024 have shown Peyman Sardari Nia Bart Scheenstra https://lnkd.in/eyiuab6s

Should patients undergoing TAVI continue to take oral anticoagulants, or will pausing their medication prior to the therapy have negative consequences? This was the question posed by Dirk-Jan van Ginkel and investigators in the POPular PAUSE TAVI trial. Their findings could have implications for the drafting of future guidelines, experts say. https://lnkd.in/eqF9UXYE

🚨 Calling all cardiovascular innovators, researchers and clinicians 🚨 The 2025 Global Cardiovascular Awards is looking for the physicians, industry leaders and ground-breaking innovations that are shaping the future of cardiovascular care. Don't miss your chance to enter. Full category details and entry requirements can be found here: https://lnkd.in/g6SdaQDu

The ShortCut leaflet splitting device from Pi-Cardia has been provided market clearance from the US Food and Drug Administration. The device is designed to enable valve-in-valve transcatheter aortic valve implantation (TAVI) procedures in patients at risk of coronary obstruction. https://lnkd.in/eSuev2-z